Investment opportunity

We are looking for funding in order to move forward with our next clinical trial. Read more below.

Why invest in Medicortex Finland Oy?

TBI is the leading cause of central nervous system impairment and there is no reliable way to detect mild injuries

Medicortex is introducing, in Finland, a new diagnostic method for a huge need – detection of brain injury and concussion.

  • Our test – detecting a biomarker in a non-invasive sample (urine or saliva) – will address a TBI point of care (POC) diagnostics market that´s estimated to exceed €2 billion annually

  • Large customer potential and variable clients

  • Current company valuation is ca. 10.5 M€.

  • Investor has an exit opportunity if the company is listed. Medicortex is pursuing a private placement during Q1 2021 in preparations for a dual listing on Nasdaq First North in Stockholm and Helsinki.

  • A team of four people keeps the costs low and the organization lean.

  • Using professional sub-contractors with qualified track record

Investments will be used for the clinical trial and product development.

  • Basic development including preclinical trial and proof-of-concept human testing has been done.

  • Patent applications and PCT have been filed.

  • Exciting Company, won twice an innovation prize.

  • The company is currently running a larger clinical trial to (up to 160 patients) to validate the clinical relevance of the biomarkers. Patient recruitment for the first part (total 69 patients) is completed. The recruitment was carried out in three Finnish hospitals; Tyks, Satakunta Central Hospital, Vaasa Central Hospital.

Go back to Investors page